KETOROLAC TROMETAMOL 30MG/ML SOLUTION FOR INJECTION
Active substance(s): KETOROLAC TROMETAMOL
KETOROLAC TROMETAMOL 30MG/ML SOLUTION FOR INJECTION
(Referred to in this leaflet as Ketorolac Injection)
Please read this leaflet carefully before being given Ketorolac Injection.
• Keep the leaflet in case you want to refer to it again
• If you want to know more about your medicine or have any questions, you should ask your
doctor or pharmacist.
In this leaflet:
1. What Ketorolac Injection is and what it is used for
2. What you need to know before you are given Ketorolac Injection
3. How Ketorolac Injection should be given
4. Possible side effects
5. Storing Ketorolac Injection
6. Contents of the pack and other information
1. WHAT KETOROLAC INJECTION IS AND WHAT IT IS USED FOR
Ketorolac belongs to a group of medicines known as non-steroidal anti-inflammatory drugs
Ketorolac Injection is used to relieve moderate or severe pain after a surgical operation.
2. WHAT YOU NEED TO KNOW
BEFORE YOU ARE GIVEN KETOROLAC INJECTION
You must not be given Ketorolac Injection and you should talk to your doctor
immediately if you:
• are allergic to Ketorolac or any of the ingredients of this medicine (see section 6)
• have had a hypersensitivity reaction to ibuprofen, aspirin or other NSAIDs
• have previously had or have peptic ulcers (ulcer in your stomach or duodenum), bleeding
in your stomach or perforation
• have or have ever had bleeding from the stomach or perforation related to use of NSAIDs
• have bleeding from a damaged blood vessel in the brain
• have problems with bleeding or blood clotting disorders
• have nasal polyps, allergic swellings (of the skin, around the mouth, eyes, nose or the
genitals) or constriction of the airways making breathing difficult
• have asthma or a history of asthma
• are taking other NSAIDs (such as ibuprofen), aspirin, oxpentifylline (to treat circulatory
disease), probenecid (to treat gout) or lithium salts (to treat nervous disorders)
• are taking medicines to thin the blood (such as warfarin or low dose heparin)
• are dehydrated or have lost a lot of blood
• have severe heart failure
• have liver failure
have recently had an operation with a high risk of bleeding or bleeding that has not been
• are about to have surgery
• have moderate or severe kidney disease, are at risk of, or have kidney failure
• are pregnant, in labour, in delivery or breast feeding
• are under 16 years of age.
Ketorolac Injection contains alcohol and is therefore not for epidural or intrathecal use (injection
into the spine)
Before you are given Ketorolac Injection, tell your doctor if you:
• have stomach problems, inflammatory bowel disease (e.g. ulcerative colitis or Crohn’s
disease) or are passing black tarry stools or blood
• have problems with your kidneys or liver
• have problems breathing
• have heart problems or high blood pressure. Medicines such as Ketorolac Injection may
be associated with a small increased risk of heart attack (“myocardial infarction”) or stroke.
Any risk is more likely with high doses and prolonged treatment. Do not exceed the
recommended dose or duration of treatment. If you have heart problems, previous stroke
or think you might be at risk of these conditions (for example if you have high blood
pressure, diabetes or high cholesterol or are a smoker) you should discuss your treatment
with your doctor or pharmacist.
• have a decrease in the usual amount of urine you pass
• have bleeding or bruising at the site of your operation
• have systemic lupus erythematosus or mixed connective tissue disorder (autoimmune
• are elderly
• are planning to become pregnant.
Pregnancy and breast-feeding
Ketorolac Injection should not be given if you are pregnant, in labour, during delivery or if you
are breast-feeding. Ketorolac may make it more difficult to become pregnant. You should tell
your doctor if you are planning to become pregnant or if you have problems becoming
Driving and using machines
Ketorolac Injection may make you feel dizzy, tired or drowsy, you may also get headaches,
visual disturbances, vertigo or have difficulty sleeping. If you experience any of these you
should not drive or operate machines.
Important information about some of the ingredients of Ketorolac Injection
This medicinal product contains 100mg of ethanol (alcohol) per dose, equivalent to 2ml beer or
1 ml wine per dose.
This may be harmful for those suffering from alcoholism, and should be taken into account in
children and high-risk groups such as those with liver disease, or epilepsy.
Information for Healthcare Professionals:
KETOROLAC TROMETAMOL 30MG/ML SOLUTION FOR INJECTION
Please read this information carefully before using Ketorolac Injection. Further information is
contained in the Summary of Product Characteristics
Ketorolac Trometamol 30mg/ml Solution for Injection (referred to as Ketorolac Injection) contains
30mg ketorolac trometamol in each 1 ml ampoule. Also contains ethanol, sodium chloride, sodium
hydroxide and water for injections.
DOSAGE AND METHOD OF ADMINISTRATION
Ketorolac Injection is suitable for use as long as it remains clear and free of precipitate. Ketorolac
Injection is for administration by intramuscular or bolus intravenous injection. Bolus intravenous
doses should be given over at least 15 seconds. Ketorolac Injection should not be used for epidural
or spinal administration.
The time to onset of analgesic effect following both IV and IM administration is approximately 30
minutes, maximum analgesia occurs within one to two hours. Analgesia normally lasts for four to six
Adults: The recommended initial dose of Ketorolac Injection is 10mg followed by 10 to 30mg every
four to six hours as required. In the initial post-operative period, Ketorolac Injection may be given as
often as every two hours if needed. The lowest effective dose should be given. A total daily dose of
90mg for non-elderly and 60mg for the elderly, patients with renal impairment and patients less than
50kg should not be exceeded. The maximum duration of treatment should not exceed two days.
Opioid analgesics (e.g. morphine, pethidine) may be used concomitantly. When used with ketorolac,
the daily dose of opioid is usually less than that normally required but opioid side effects should still
be considered. Elderly patients should be monitored for GI bleeding.
Patients receiving Ketorolac Injection and oral ketorolac should receive a total combined daily dose
not exceeding 90mg (60mg for the elderly, patients with renal impairment and patients less than
50kg). The oral component should not exceed 40mg on the day the change of formulation is made.
Patients should be converted to oral treatment as soon as possible.
Children: Ketorolac Injection is not recommended for use in children under 16 years of age.
• active peptic ulcer, or history of gastrointestinal bleeding, ulceration or perforation
• active or history of gastrointestinal bleeding or perforation related to previous NSAID therapy
• suspected or confirmed cerebrovascular bleeding
• haemorrhagic diatheses, including coagulation disorders
• hypersensitivity to ketorolac trometamol or any of the excipients
• previous sensitivity to ibuprofen aspirin or other NSAIDs
• patients with complete or partial syndrome of nasal polyps, angioedema or bronchospasm
• concurrent treatment with aspirin or other NSAIDs including cylcooxygenase 2 specific
inhibitors, oxpentifylline, probenecid or lithium salts
• moderate or severe renal impairment (serum creatinine >160 micromol/l) or patients at risk of
renal failure due to hypovolaemia or dehydration
• a history of asthma
• patients who have had operations with a high risk of haemorrhage or incomplete haemostasis
and those with haemorrhagic diseases including coagulation disorders
• patients on anti-coagulants including warfarin and low dose heparin
• severe heart failure, liver failure and renal failure
• during pregnancy, labour, delivery or lactation
Other medicines and Ketorolac Injection
See Section 2 for medicines that should not be taken with Ketorolac Injection.
Tell your doctor if you are taking, or have recently taken, any other medicine – even those not
prescribed. This is important because ketorolac could alter how other medicines work.
These include medicines for:
• blood clots (anti-coagulants, oxpentifylline, antiplatelet agents)
• heart failure (furosemide, diuretics or cardiac glycosides such as digoxin)
• depression (lithium, selective serotonin reuptake inhibitors - SSRIs)
• high blood pressure (diuretics, ACE inhibitors, thromboxane, angiotensin II inhibitors)
• gout (probenecid), psoriasis (methotrexate), inflammation or arthritis (steroids)
• other NSAIDs (such as ibuprofen) or aspirin
• acute organ rejection (ciclosporin, tacrolimus)
• infections (quinolone antibacterials)
• HIV and AIDs (zidovudine)
• or a drug called mifepristone (used to induce abortion, usually through hospitals).
Ketorolac should not be used for 8 - 12 days after taking mifepristone.
3. HOW KETOROLAC INJECTION SHOULD BE GIVEN
You will normally be given Ketorolac Injection whilst in hospital. A doctor or nurse will give the
injection into a muscle or a vein.
The usual dose is 10mg initially, followed by 10-30mg every 4 to 6 hours. The dose may be
lowered if you are over 65 years of age, you have kidney problems or if you weigh less than
The maximum duration of treatment should not be more than 2 days.
If you have the impression that the effect of Ketorolac Injection is too strong or too weak, talk to
4. POSSIBLE SIDE EFFECTS
Like other medicines, Ketorolac Injection may cause side effects in some patients. Most
patients are given ketorolac without experiencing problems.
Serious side effects
Tell your doctor IMMEDIATELY if any of the following occur:
• difficulty in breathing or wheezes, swelling of the face, lips or throat, itching or flaky skin,
rash, spots or blisters on the skin. You may have an allergic reaction, which can be very
• you pass blood in your faeces (stools/motions)
• you pass black tarry stools
• you vomit any blood or dark particles that look like coffee grounds.
• serious illness with blistering of the skin, mouth, eyes and genitals called Stevens-Johnson
Other side effects
Tell your doctor or nurse if you have any of the following:
• feeling sick or being sick, indigestion or heart burn, stomach pain or discomfort,
inflammation of the stomach, bleeding, problems with the pancreas, stomach ulcer,
diarrhoea, belching, constipation or wind, feeling of fullness, feeling unwell
anxiety, drowsiness, tiredness, dizziness, headache, sweating, fever, agitation,
nervousness, mental disturbances, mood changes, confusion, abnormal thinking and
feelings, inability to concentrate, inability to sleep, convulsions, giddiness, hyperactivity, a
mild form of meningitis, hallucinations, abnormal dreams
dry mouth, mouth ulcers, sore throat, excessive thirst, weight gain, fever, alterations of
vision, taste or hearing (loss of hearing, ringing in the ears, vertigo)
muscle pain, numbness or tingling, muscle spasms or weakness
kidney problems, a change in the amount of urine passed or frequency in going to the
toilet, blood in the urine, fluid retention, weight gain, kidney pain or kidney failure
facial redness or paleness, flushing, bruising, anaemia, changes in the blood
changes in blood pressure, palpitations, chest pain or slow heart beat. Medicines such as
Ketorolac Injection may be associated with a small risk of increased heart attack
(“myocardial infarction”) or stroke
bleeding from the site of the operation or bruising or a nose bleed
sensitivity of the skin to light
pain at the site of injection
jaundice (yellowing of the skin and whites of the eyes), liver failure and inflammation of the
liver have been reported very rarely.
Reporting of side effects
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible
side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card
Scheme at: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
5. STORING KETOROLAC INJECTION
The hospital will store the medicines. Ketorolac Injection should not be stored above 30°C. It
should be kept in the original container and protected from light. Keep out of reach and sight of
Use by date: Ketorolac Injection should not be used after the date on the carton.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What is in this medicine:
Each 1 ml ampoule contains 30mg of the active ingredient ketorolac trometamol.
The ampoules also contain ethanol, sodium chloride, sodium hydroxide and water for injections.
What this medicine looks like and contents of the pack:
Ketorolac Injection is a colourless or slightly yellowish solution in amber glass ampoules. Each
pack contains 6 or 100 ampoules.
Marketing authorisation holder: Beacon Pharmaceuticals Limited, DCC Vital, Westminster
Industrial Estate, Repton Road, Measham, DE12 7DT, England.
Manufacturer: Laboratorio Reig Jofré S.A, Barcelona, Spain.
Date of last revision: 02/2017
children under 16 years of age
Ketorolac is contra-indicated as prophylactic analgesia before surgery and intra-operatively. It
must not be used for neuraxial administration due to its alcohol content.
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Ketorolac should not be used with other NSAIDs or in patients receiving aspirin because of the
increased risk of inducing serious NSAID-related side-effects.
Ketorolac injection is contraindicated in combination with anti-coagulants such as warfarin, low dose
heparin or dextran since co-administration may cause an enhanced anti-coagulant effect.
Ketorolac inhibits platelet aggregation, reduces thromboxane concentrations and prolongs bleeding
time. Ketorolac may reduce the diuretic response to furosemide (approx. 20%) so particular care
should be taken in patients with cardiac decompensation. Co-administration with diuretics can lead to
a reduced diuretic effect and risk of nephrotoxicity.
NSAIDs may reduce the effects of diuretics and anti-hypertensives. The risk of acute renal
insufficiency may be increased when administered concurrently with ACE inhibitors and/or
angiotensin II inhibitors, particularly in some patients with compromised renal function..
NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycoside levels
when co-administered with cardiac glycosides.
Care is advised when methotrexate is co-administered. Some prostaglandin synthesis inhibiting
drugs may reduce the clearance of methotrexate, possibly enhancing its toxicity.
Probenecid should not be administered concurrently with ketorolac because of decreased plasma
clearance and volume of distribution leading to increases in ketorolac plasma level and half-life.
As with all NSAIDs caution is advised when ciclosporin or tacrolimus is co-administered because of
the increased risk of nephrotoxicity.
NSAIDs should not be used for 8-12 days after mifepristone. NSAIDs can reduce the effects of
Caution should be taken when co-administering with corticosteroids because of the increased risk of
Patients taking quinolones may have an increased risk of developing convulsions because of an
increased tendency to bleeding co-administration with oxpentifylline should be avoided.
In patients receiving lithium there is a possible inhibition of renal lithium clearance, leading to an
increased plasma lithium concentration.
Antiplatelet agents and SSRIs may increase the risk of GI bleeding.
Co-administration with Zidovudine may result in haematological toxicity.
Ketorolac Injection should not be mixed in a small volume (e.g. in a syringe) with morphine sulfate,
pethidine hydrochloride, promethazine hydrochloride or hydroxyzine hydrochloride, as precipitation of
ketorolac will occur.
Ketorolac Injection is compatible with normal saline, 5% dextrose, Ringer's, lactated Ringer's or
Plasmacyte solutions. Compatibility of Ketorolac Injection with other drugs is unknown.